Primarily used in the production of alcoholic
beverages, especially beer, hops represent another large
market for CELEXT07 in addition to cannabis.
MONTREAL, May 16, 2019 /CNW/ - Mondias Naturals
Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to
announce the results from research on the use of its proprietary
CELEXT07 bio-defense stimulant plant extract on hops plants,
conducted in collaboration with McGill
University.
Global hops production is expected to grow by 3.3% to 122,767
metric tons in 2019 (Source: IHGC - Economic Commission Summary
Reports, April 26, 2019). Hops
production in the United States
alone reached a record high of US$618
million in 2017, up 24% from US$498
million in 2016 (Source: U.S. Department of
Agriculture). The global hops market is driven by increasing
demand for hops in alcoholic beverages, medicinal drugs and
cosmetic formulations. Over the next five years, increased demand
for various flavours in beer such as pilsner or lager and the rise
in popularity for hop-based craft beer are major factors that will
significantly fuel the growth of the global hops market (Source:
Persistence Market Research).
The objective of the current series of tests was to measure
CELEXT07's efficacy in suppressing and preventing diseases on hops
plants. Hops is a genus belonging to the same taxonomic family as
cannabis. Mondias' latest experiments on cannabis and hops served
as proof-of-concept of the efficacy of the Company's botanicals in
plant protection and increasing plant survival by eliciting induced
resistance.
Summary of the test results:
- Foliar applications of CELEXT07 bio-defense stimulant extract
were very effective in suppressing grey mould (caused by
Botrytis cinerea) infections on hops, with decreases of 86%
in disease severity and 67% in disease incidence.
- A scheduled dose split over three days for the soil drench
application of CELEXT07 also proved effective for the
prevention/suppression of grey mould on hops, with decreases of 31%
in disease severity and up to 50% in disease incidence.
- Foliar and soil drench application of CELEXT07 did not have any
phytotoxic effect on hops.
"These latest results continue to confirm that CELEXT07 is very
effective in suppressing and preventing a wide range of fungal and
bacterial pathogens, and has applications in more than one large
market," said Jean-Philippe Gravel,
Chief Executive Officer of Mondias. "As mentioned in our last
release, Mondias has secured the production capacity needed to meet
demand from potential clients. CELEXT07 is ready to market and we
are presently looking at selling our product through various sales
channels and markets, including the agriculture, horticulture,
cannabis and hops markets."
With post-harvest losses of one-third of the food produced
worldwide for human consumption (Gastavsson et al., 2011) and
annual economic losses of $10 billion
to $100 billion worldwide due to grey
mould and powdery mildew (L. Hua et al., 2018), the market
potential for CELEXT07 is considerable.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the health care,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries and greenhouses, in collaboration with McGill's Faculty of Agricultural and Environmental
Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the Company's inability to
obtain sufficient financing to execute its business plan;
competition; regulation; anticipated and unanticipated costs and
delays; the success of the Company's research and development
strategies; the ability to obtain orphan drug status; the
applicability of the discoveries made; the successful and timely
completion and uncertainties related to the regulatory approval
process; the timing of clinical trials; the timing and outcomes of
regulatory or intellectual property decisions; and other risks
disclosed in the Company's public disclosure record on file with
the relevant securities regulatory authorities. Although the
Company has attempted to identify important factors that could
cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors
that cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on
forward-looking statements. The forward-looking statements in this
news release are made as of the date of this news release, and the
Company does not undertake any obligation to publicly update them
to reflect new information or subsequent events or otherwise unless
required by applicable securities legislation.
SOURCE Mondias Natural Products Inc.